Eagle Pharmaceuticals Inc (EGRX) — Cash Flow Reinvestment Rate
Eagle Pharmaceuticals Inc (EGRX) has a Cash Flow Reinvestment Rate of 0.00x as of December 2022, reinvesting $19.00K (capex $10.00K plus investments $-9.00K) from operating cash flow of $37.56 Million. Check EGRX cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Eagle Pharmaceuticals Inc Cash Flow Reinvestment Rate (2016–2022)
Historical reinvestment intensity for Eagle Pharmaceuticals Inc across 7 annual periods. Explore Eagle Pharmaceuticals Inc (EGRX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Eagle Pharmaceuticals Inc (2016–2022)
Year-by-year capital reinvestment analysis for Eagle Pharmaceuticals Inc. For live market cap and broader valuation context, see Eagle Pharmaceuticals Inc (EGRX) total market value.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 2.83x | $87.01 Million | $30.80 Million | $178.00K | ▲ +1312.1% |
| 2021 | 0.20x | $5.65 Million | $28.22 Million | $323.00K | ▼ -47.9% |
| 2020 | 0.38x | $18.99 Million | $49.50 Million | $747.00K | ▲ +1282.5% |
| 2019 | 0.03x | $1.55 Million | $55.99 Million | $777.00K | ▲ +446.6% |
| 2018 | 0.01x | $266.00K | $52.38 Million | $133.00K | ▼ -97.1% |
| 2017 | 0.18x | $10.37 Million | $58.92 Million | $5.19 Million | ▼ -85.9% |
| 2016 | 1.25x | $66.49 Million | $53.21 Million | $20.69 Million | — |